- Home
- GHRS vs MLTX Comparison
GHRS vs MLTX Comparison
Compare GHRS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | MLTX |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | Ireland | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GHRS | MLTX |
|---|---|---|
| Price | $15.15 | $15.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $32.90 | $22.22 |
| AVG Volume (30 Days) | 248.6K | ★ 1.4M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.98 | $5.95 |
| 52 Week High | $19.51 | $62.75 |
Technical Indicators
Market Signals| Indicator | GHRS | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 52.03 |
| Support Level | $13.60 | $14.47 |
| Resistance Level | $15.88 | $16.15 |
| Average True Range (ATR) | 0.94 | 0.79 |
| MACD | -0.20 | -0.12 |
| Stochastic Oscillator | 42.46 | 54.63 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.